New asciminib oxalate salt, is Bcr-Abl tyrosine kinase inhibitor used in pharmaceutical composition for treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
	PAL S; CHOWDARY N S
	2023-09-08
专利权人	DR REDDY'S LAB LTD (REDY-C)
申请日期	2023-09-08
专利号	IN202341060349-A
成果简介	NOVELTY - Asciminib oxalate salt, is new. USE - Asciminib oxalate salt used in pharmaceutical composition (claimed) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. No biological data is given. ADVANTAGE - The asciminib oxalate (Ccrystalline form DC1) has a high storage stability. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: 1. a crystalline form DC1 of Asciminib oxalate, characterized by a Powder X-Ray Diffraction (PXRD) comprising the peaks at 9.57, 11.2, 13.8, 18.4, 19.3, 20.1, 21.9, 22.7, 23.6, 24.3, 25.5, 27.5, 30.0, 31.3, 33.3 ± 0.2 2θ; 2. a method for the preparing of a crystalline form DC1 of asciminib oxalate which involves: (a) providing a mixture of asciminib free base and oxalic acid in presence of a solvent; and (b) isolating the crystalline form DC1 of asciminib oxalate; 3. a crystalline form DC2 of asciminib phosphate, characterized by a PXRD comprising the peaks at 6.4, 8.0, 10.0, 14.4, 14.8, 15.4, 17.9, 18.7, 19.3, 20.1, 21.2, 22.3, 22.7, 24.4, 27.3, 30.6, 31.8, 33.1 ± 0.2 2θ; 4. a method for preparing the crystalline form DC2 of asciminib phosphate, which comprises (a) providing a solution of asciminib phosphate in propylene glycol; and (b) isolating the crystalline form DC2 of asciminib phosphate; 5. an asciminib trifluoro acetate salt; 6. a crystalline form DC3 of asciminib trifluoro acetate, characterized by a PXRD comprising the peaks at 7.1, 8.5, 9.6, 11.4, 12.0, 14.4, 15.8, 17.0, 17.5, 18.2, 19.2, 19.6, 20.3, 21.4, 22.0, 23.0, 24.1, 25.5, 26.5, 28.0, 29.0, 30.3, 31.0, 32.4, 35.3 ± 0.2 2θ; 7. a method for the preparing the crystalline form DC3 of asciminib trifluoro acetate, which involves (a) providing a mixture of asciminib with trifluoro acetic acid in present of a solvent; and (b) isolating the crystalline form DC3 of asciminib trifluoro acetate; and 8. a pharmaceutical composition, which comprises crystalline form DC1 of asciminib oxalate or crystalline form DC2 of asciminib phosphate or crystalline form DC3 of asciminib trifluoro acetate with at least one pharmaceutical excipient.
IPC 分类号	A61K-031/4439 ; A61P-035/02 ; C07D-401/14
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/20451
专题	中国科学院新疆生态与地理研究所
作者单位	DR REDDY'S LAB LTD (REDY-C)
推荐引用方式 GB/T 7714	PAL S,CHOWDARY N S. New asciminib oxalate salt, is Bcr-Abl tyrosine kinase inhibitor used in pharmaceutical composition for treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. IN202341060349-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。